Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

TVGN vs IMVT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TVGN
Tevogen Bio Holdings Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.48B
5Y Perf.-98.5%
IMVT
Immunovant, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$5.53B
5Y Perf.+289.4%

TVGN vs IMVT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TVGN logoTVGN
IMVT logoIMVT
IndustryBiotechnologyBiotechnology
Market Cap$1.48B$5.53B
Revenue (TTM)$0.00$0.00
Net Income (TTM)$-31M$-464M
Total Debt$3M$98K
Cash & Equiv.$1M$714M

TVGN vs IMVTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TVGN
IMVT
StockJan 22May 26Return
Tevogen Bio Holding… (TVGN)1001.5-98.5%
Immunovant, Inc. (IMVT)100389.4+289.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: TVGN vs IMVT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: IMVT leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
TVGN
Tevogen Bio Holdings Inc.
The Growth Play

TVGN is the clearest fit if your priority is growth exposure.

  • EPS growth 47.6%
Best for: growth exposure
IMVT
Immunovant, Inc.
The Income Pick

IMVT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • beta 1.37
  • 173.6% 10Y total return vs TVGN's -98.5%
  • Lower volatility, beta 1.37, Low D/E 0.0%, current ratio 11.16x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthIMVT logoIMVT-21.3% revenue growth vs TVGN's -6.7%
Quality / MarginsIMVT logoIMVT3.2% margin vs TVGN's -5.3%
Stability / SafetyIMVT logoIMVTBeta 1.37 vs TVGN's 2.02
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)IMVT logoIMVT+96.1% vs TVGN's -85.6%
Efficiency (ROA)IMVT logoIMVT-44.1% ROA vs TVGN's -6.9%

TVGN vs IMVT — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLIMVTLAGGINGTVGN

Income & Cash Flow (Last 12 Months)

IMVT leads this category, winning 1 of 1 comparable metric.

TVGN and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.

MetricTVGN logoTVGNTevogen Bio Holdi…IMVT logoIMVTImmunovant, Inc.
RevenueTrailing 12 months$0$0
EBITDAEarnings before interest/tax-$30M-$487M
Net IncomeAfter-tax profit-$31M-$464M
Free Cash FlowCash after capex-$13M-$423M
Gross MarginGross profit ÷ Revenue
Operating MarginEBIT ÷ Revenue
Net MarginNet income ÷ Revenue
FCF MarginFCF ÷ Revenue
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year+13.5%+19.7%
IMVT leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

TVGN leads this category, winning 1 of 1 comparable metric.
MetricTVGN logoTVGNTevogen Bio Holdi…IMVT logoIMVTImmunovant, Inc.
Market CapShares × price$1.5B$5.5B
Enterprise ValueMkt cap + debt − cash$1.5B$4.8B
Trailing P/EPrice ÷ TTM EPS-79.91x-9.97x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue
Price / BookPrice ÷ Book value/share5.83x
Price / FCFMarket cap ÷ FCF
TVGN leads this category, winning 1 of 1 comparable metric.

Profitability & Efficiency

IMVT leads this category, winning 3 of 4 comparable metrics.

On the Piotroski fundamental quality scale (0–9), TVGN scores 4/9 vs IMVT's 2/9, reflecting mixed financial health.

MetricTVGN logoTVGNTevogen Bio Holdi…IMVT logoIMVTImmunovant, Inc.
ROE (TTM)Return on equity-47.1%
ROA (TTM)Return on assets-6.9%-44.1%
ROICReturn on invested capital
ROCEReturn on capital employed-66.1%
Piotroski ScoreFundamental quality 0–942
Debt / EquityFinancial leverage0.00x
Net DebtTotal debt minus cash$2M-$714M
Cash & Equiv.Liquid assets$1M$714M
Total DebtShort + long-term debt$3M$98,000
Interest CoverageEBIT ÷ Interest expense-219.56x
IMVT leads this category, winning 3 of 4 comparable metrics.

Total Returns (Dividends Reinvested)

IMVT leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $151 for TVGN. Over the past 12 months, IMVT leads with a +96.1% total return vs TVGN's -85.6%. The 3-year compound annual growth rate (CAGR) favors IMVT at 12.1% vs TVGN's -76.0% — a key indicator of consistent wealth creation.

MetricTVGN logoTVGNTevogen Bio Holdi…IMVT logoIMVTImmunovant, Inc.
YTD ReturnYear-to-date-58.9%+5.1%
1-Year ReturnPast 12 months-85.6%+96.1%
3-Year ReturnCumulative with dividends-98.6%+40.9%
5-Year ReturnCumulative with dividends-98.5%+62.4%
10-Year ReturnCumulative with dividends-98.5%+173.6%
CAGR (3Y)Annualised 3-year return-76.0%+12.1%
IMVT leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

IMVT leads this category, winning 2 of 2 comparable metrics.

IMVT is the less volatile stock with a 1.37 beta — it tends to amplify market swings less than TVGN's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs TVGN's 9.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTVGN logoTVGNTevogen Bio Holdi…IMVT logoIMVTImmunovant, Inc.
Beta (5Y)Sensitivity to S&P 5002.02x1.37x
52-Week HighHighest price in past year$75.50$30.09
52-Week LowLowest price in past year$0.35$13.36
% of 52W HighCurrent price vs 52-week peak+9.9%+90.5%
RSI (14)Momentum oscillator 0–10053.860.2
Avg Volume (50D)Average daily shares traded34K1.4M
IMVT leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates TVGN as "Hold" and IMVT as "Buy".

MetricTVGN logoTVGNTevogen Bio Holdi…IMVT logoIMVTImmunovant, Inc.
Analyst RatingConsensus buy/hold/sellHoldBuy
Price TargetConsensus 12-month target$45.50
# AnalystsCovering analysts123
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

IMVT leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TVGN leads in 1 (Valuation Metrics).

Best OverallImmunovant, Inc. (IMVT)Leads 4 of 6 categories
Loading custom metrics...

TVGN vs IMVT: Frequently Asked Questions

7 questions · data-driven answers · updated daily

01

Is TVGN or IMVT a better buy right now?

Analysts rate Immunovant, Inc.

(IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — TVGN or IMVT?

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -98. 5% for Tevogen Bio Holdings Inc. (TVGN). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus TVGN's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — TVGN or IMVT?

By beta (market sensitivity over 5 years), Immunovant, Inc.

(IMVT) is the lower-risk stock at 1. 37β versus Tevogen Bio Holdings Inc. 's 2. 02β — meaning TVGN is approximately 47% more volatile than IMVT relative to the S&P 500.

04

Which has better profit margins — TVGN or IMVT?

Tevogen Bio Holdings Inc.

(TVGN) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TVGN leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — TVGN leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

05

Which pays a better dividend — TVGN or IMVT?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

06

Is TVGN or IMVT better for a retirement portfolio?

For long-horizon retirement investors, Immunovant, Inc.

(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+173. 6% 10Y return). Tevogen Bio Holdings Inc. (TVGN) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMVT: +173. 6%, TVGN: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

07

What are the main differences between TVGN and IMVT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

TVGN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

IMVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.